Brief: Nextcure Provides Interim Update Of Phase 2 Portion Of Monotherapy Phase Trial, Announces Departure Of Chief Medical Officer

NextCure

13/07/2020 13:45

July 13 (Reuters) - NextCure Inc  NXTC.O :
    * NEXTCURE PROVIDES AN INTERIM UPDATE OF THE PHASE 2 PORTION
OF
THE NC318 MONOTHERAPY PHASE 1/2 TRIAL AND ANNOUNCES DEPARTURE OF
CHIEF MEDICAL OFFICER
    * NEXTCURE INC - WILL EVALUATE WHETHER TO PURSUE ADDITIONAL
MONOTHERAPY STUDIES IN NSCLC AND OVARIAN CANCER AFTER A REVIEW
OF THAT INFORMATION
    * NEXTCURE - DOES NOT PLAN TO ADVANCE NON-SMALL CELL LUNG
CANCER
(NSCLC) AND OVARIAN CANCER COHORTS INTO STAGE 2 PORTION OF SIMON
2-STAGE TRIAL
    * NEXTCURE INC - CONTINUES TO ENROLL IN HEAD AND NECK
SQUAMOUS
CELL CARCINOMA (HNSCC) AND TRIPLE-NEGATIVE BREAST CANCER COHORTS
    * NEXTCURE INC - KEVIN N. HELLER, HAS RESIGNED, EFFECTIVE
AUGUST
4, 2020
    * NEXTCURE - EXPECT TO PROVIDE AN NC318 CLINICAL DATA UPDATE
AND
ADDITIONAL BIOMARKER DATA IN Q4 OF 2020

Source text for Eikon:  ID:nGNX1pGbSg 
Further company coverage:  NXTC.O 

 ((Reuters.Briefs@thomsonreuters.com;))